I-Mab (IMAB) Scheduled to Post Quarterly Earnings on Thursday

I-Mab ( NASDAQ:IMAB – Get Free Report ) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, November 14th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter.

I-Mab ( NASDAQ:IMAB – Get Free Report ) last issued its quarterly earnings data on Wednesday, August 28th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.



51) by $0.44. On average, analysts expect I-Mab to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

I-Mab Trading Down 3.5 % Shares of NASDAQ IMAB opened at $1.09 on Thursday.

I-Mab has a 1 year low of $0.99 and a 1 year high of $2.54.

The company’s 50-day moving average is $1.20 and its 200 day moving average is $1.44.

Wall Street Analysts Forecast Growth View Our Latest Analysis on IMAB About I-Mab ( Get Free Report ) I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. See Also Five stocks we like better than I-Mab How to Use the MarketBeat Dividend Calculator What a Trump Win Looks Like for the Market Now and Into 2025 How to Calculate Stock Profit Russell 2000 Surge Post-Election: How to Play the Small-Cap Pop Insider Buying Explained: What Investors Need to Know Macro Headwinds Send Microchip Technology Stock to the Buy Zone Receive News & Ratings for I-Mab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for I-Mab and related companies with MarketBeat.

com's FREE daily email newsletter ..